

# THE CAMPBELL FOUNDATION

GRANT HISTORY  
1995-Present

Scroll down within document to read



| YEAR | AMOUNT | GRANT RECIPIENT | GRANT TITLE |
|------|--------|-----------------|-------------|
|------|--------|-----------------|-------------|

|      |          |  |  |
|------|----------|--|--|
| 2022 | \$50,00  | Harvard  | <a href="#"><u>Characterizing the HIV-1 Reservoir Landscape in HIV-1 Clade Infected Adolescents &amp; Young Adults from Botswana</u></a>   |
| 2022 | \$90,000 | UCLA   | <a href="#"><u>Escape from HIV-Specific Chimeric Antigen Receptors</u></a>   |
| 2021 | \$80,000 | The Wistar Institute                                 | <a href="#"><u>“Role of Intestinal Barrier Integrity and Antibody Glycosylation in Long-COVID During HIV-infection”</u></a>  |
| 2021 | \$85,000 | HIV-Assist   | <a href="#"><u>Improving prevision HIV care through a mobile device application for evidence-based decision and education support for antiretroviral selection</u></a>   |
| 2021 | \$90,000 | Weill Cornell Medicine<br>Clinical Directors Network | <a href="#"><u>Investigating the Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) for Measures of Cardiovascular Disease and Neurologic Outcomes in People Living with HIV-1</u></a> |
| 2020 | \$80,00  | University of Miami Miller School                    | <a href="#"><u>Anti-HIV Antibodies for Effective &amp; durable Adeno-Associated Virus (AAV) Delivery</u></a>   |
| 2020 | \$85,000 | Burnet Institute                                     | <a href="#"><u>Enhancing the Vaginal Environment and Microbiota (EVE-M) to Prevent HIV Transmission</u></a>  |
| 2020 | \$80,000 | Tel Aviv University                                  | <a href="#"><u>Using the Germline Precursors of the Anti-HIV Broadly Neutralizing Antibody BG18 as a Template for HIV Vaccine Design</u></a>   |
| 2018 | \$75,000 | McGovern Medical School at UTHealth                  | <a href="#"><u>Mechanisms of Fibrosis in Chronic Treated HIV Infection</u></a>   |

|      |           |   |   |
|------|-----------|---|---|
| 2018 | \$88,000  | Tufts University School of Medicine   | <a href="#">Linking Structural Dynamics of HIV-1 Env to Correlates of Immunoprotection in the RV144 Vaccine Trial</a> |
| 2018 | \$75,000  | Stanford University School of Medicine  | <a href="#">A Combined Drug Resistance and Virus Load Point of Care Assay</a>   |
| 2018 | \$100,000 | The Wistar Institute  | <a href="#">Role of Host Glycosylation in the Galectin-9-Mediated Reversal of HIV Latency</a>                         |
| 2017 | \$80,000  | The Ohio State University College of Medicine                                   | <a href="#">Grant to Develop Gene Editing Tool to Destroy Latent HIV Cells in Lymph Nodes</a>                         |
| 2017 | \$10,000  | The Montrose Center   | <a href="#">Hurricane Harvey Emergency Grant</a>  |
| 2017 | \$10,000  | AIDS Foundation Houston   | <a href="#">Hurricane Harvey Emergency Grant</a>  |
| 2017 | \$75,000  | David Geffen School of Medicine at UCLA   | <a href="#">Novel Therapies for HIV-Related Aging of the Immune System</a>  |
| 2017 | \$25,000  | Miami Center for AIDS Research<br>University of Miami Miller School of Medicine | <a href="#">Local Research Grant Initiative</a>   |
| 2017 | \$25,000  | Broward Health Comprehensive Care Center  |   |
| 2017 | \$25,000  | Herbert Wertheim College of Medicine at FIU                                     | <a href="#">Local Research Grant Initiative</a>   |
|      |           |   | <a href="#">Local Research Grant Initiative</a>   |

|      |           |   |   |
|------|-----------|---|---|
| 2017 | \$85,000  | <a href="#">Indiana University School of Medicine</a>           | <a href="#">Probenecid-Boosted Tenofovir: A New Strategy for On-Demand HIV Pre-Exposure Prophylaxis</a>                         |
| 2016 | \$77,495  | Massachusetts General Hospital                                  | <a href="#">Brain inflammation and cognitive decline in HIV patients with dysbiotic microbiome</a>                              |
| 2016 | \$79,151  | Scripps Research Institute, Jupiter, FL                         | <a href="#">Targeting HIV-1 Latent Infection with a Potent Tat Inhibitor</a>  |
| 2016 | \$80,000  | Northwestern University   | <a href="#">Controlling HIV Release from Cells with First-in-Class Drugs Targeting Virus Budding</a>                            |
| 2016 | \$75,000  | Drexel University College of Medicine                           | <a href="#">Long-Acting Formulation for the Systemic Delivery of HIV-1 Inactivators Using Metamorphic T-Cell-like Liposomes</a> |
| 2015 | \$60,000  | Columbia University Medical Center                              | <a href="#">Arterial Wall Infection by HIV as a Trigger for Arterial Wall Inflammation</a>                                      |
| 2015 | \$48,900  | <a href="#">Case Western/Rainbow Babies Hospital</a>            | <a href="#">Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV-infected Children and Healthy Controls</a>        |
| 2015 | \$30,000  | Children's Diagnostic & Treatment Center                        | <a href="#">Local Research Grant Initiative</a>   |
| 2015 | \$30,000  | University of Miami Miller School of Medicine                   | <a href="#">Local Research Grant Initiative</a>   |
| 2015 | \$30,000  | Florida Atlantic University Charles Schmidt College of Medicine | <a href="#">Local Research Grant Initiative</a>   |
| 2015 | \$100,000 | Ben-Gurion University, Israel                                   | <a href="#">Efficacy of Tenofovir Delivered to the Brain by Novel Nanovesicles in a Neuro-HIV Mouse Model</a>                   |
| 2014 | \$50,000  | amfAR   | <a href="#">Countdown to a Cure Matching Grant Program</a>  |
| 2014 | \$85,000  | Children's Hospital Boston at Harvard                           | <a href="#">Novel Mechanisms Regulating HIV-1 Latency in HIV/TB Co-Infection</a>  |

|      |           |   |   |
|------|-----------|---|---|
| 2014 | \$79,375  | The George Washington University        | Defining the Unique Biomarkers of Latently Infected T-Cells   |
| 2014 | \$88,415  | Johns Hopkins University Medical School | Pharmacokinetics and Pharmacodynamics of the Etonogestrel Implant When Co-administered With Efavirenz                         |
| 2014 | \$79,954  | VA Medical Center, Vermont              | Blocking CXCL9 to Improve Anti-HIV Potency of Tenofovir   |
| 2013 | \$100,000 | Mount Sinai School of Medicine          | Simultaneous Disruption of Latency & Immune Enhancement by Poly ICLC During HIV-1 Infection                                   |
| 2013 | \$88,000  | Univ. of Pittsburgh                     | MicroRNAs as Biomarkers for HIV-1 Associated Neurocognitive Impairment & Dementia: Development of a Sensitive Diagnostic Tool |
| 2013 | \$50,000  | R.A.I.N., Oklahoma City                 | Emergency Relief Grant  |
| 2013 | \$86,431  | Univ. of California, Davis              | Pre-Selective Anti-HIV Vectors for Improved HIV Stem Cell Gene Therapy  |
| 2012 | \$73,047  | Washington University                   | Topical Fusogenic Nanosnares for HIV Prophylaxis  |
| 2012 | \$82,500  | UCSF                                    | Restriction of HIV Replication  |
| 2012 | \$100,000 | Mount Sinai School of Medicine          | Isolation of Novel Prothymosin-a Variants with Potent Anti-HIV & Interferon Inducing Activities                               |
| 2012 | \$86,130  | Ben-Gurion University                   | Delivery of Tenofovir to the Brain by Novel Nanovesicles for the Treatment of Neuro-HIV                                       |
| 2012 | \$78,479  | University of Minnesota                 | Investigation of a Novel Chemotherapy to Target HIV Infectivity   |
| 2011 | \$32,919  | Univ. of Miami                          | Host Apolipoprotein E Affects Development of HIV-Ass'd Neurological Disease   |
| 2011 | \$25,000  | AIDS Alabama                            | Emergency Relief Grant  |

|      |          |                                    |   |
|------|----------|------------------------------------|---|
| 2011 | \$60,000 | Pennsylvania State University      | Alternative Therapies to Combat HIV: Targeting Tat by Natural Products  |
| 2011 | \$77,000 | UC Davis                           | Role of the MSS1 Protein in HIV-1/SIV Replication & Pathogenesis  |
| 2011 | \$85,000 | UCLA                               | Telmisartan and Flow-Mediated Dilatation in Older HIV+ Patients at Risk for Cardio Disease                        |
| 2011 | \$20,000 | UCLA                               | Assessing Cardio Risk & Impact of Hep C Treatment on Cardio Risk Biomarkers                                       |
| 2011 | \$50,000 | AMFAR                              | ARCHE Program Grant   |
| 2010 | \$55,000 | Washington University, St. Louis   | Dipeptidyl Peptidase-4 Inhibition & Immune Function in HIV  |
| 2010 | \$44,000 | Univ. of Southern California       | Identification of Novel Cellular Cofactors of HIV   |
| 2010 | \$70,000 | Univ. of Vermont                   | Targeting Human Proteins for Treatment of Cryptosporidiosis   |
| 2010 | \$28,435 | Dartmouth-Hitchcock Medical Center | Semen Protects Target CD4+ Cells from HIV Infection   |
| 2010 | \$51,953 | UC Davis                           | Flash-Heating Breast Milk to Decrease Morbidity, Improve Growth, & Reduce HIV Transmission in HIV-Exposed Infants |
| 2010 | \$64,327 | Rush Univ. Medical Center          | Acupuncture to Reduce HIV-Associated Inflammation   |
| 2010 | \$71,815 | UC San Diego                       | Prosp. Study of Vitamin D on Cutaneous Innate Immune Responses in HIV+ Subjects w/ and w/out CA-MRSA              |
| 2009 | \$40,000 | Burnet Institute, Australia        | Adaptive Changes in HIV Subtype C Envelope Glycoproteins Contributing to Pathogenicity                            |
| 2009 | \$45,047 | Brigham & Women's Hospital         | Detection of Minority HIV-1 Variants by Deep Sequencing   |

|      |           |                                     |  |
|------|-----------|-------------------------------------|--|
| 2009 | \$35,000  | Univ. of Minnesota                  | Enabling Lethal Restriction of HIV-1 by Human APOBEC3G                                       |
| 2009 | \$88,000  | Univ. of California, San Francisco  | Importance of Plasmacytoid Dendritic Cells in HIV Infection                                  |
| 2008 | \$96,381  | New York Blood Center               | Developing Cell Penetrating Peptides as HIV-1 Assembly Inhibitors                            |
| 2008 | \$33,500  | Emory University                    | Mechanisms of Antiviral Activity of TRIM-5 Alpha Protein                                     |
| 2008 | \$105,039 | Population Council                  | A Novel DARPins Strategy for Combating HIV   |
| 2008 | \$43,054  | Imperial College London             | Gene Expression Microarray Analysis of NK Cell Function in the Gastro. Tract of HIV+ People  |
| 2007 | \$65,700  | University of Minnesota             | Impact of Human APOBEC3 Proteins on HIV Drug Resistance                                      |
| 2007 | \$80,000  | University at Buffalo               | Novel Assays for Antiretroviral Intra/Extracellular Measurements                             |
| 2007 | \$81,000  | Roger Williams Medical Center       | Enhancing Potency of Anti-HIV Chimeric Immune Receptors                                      |
| 2007 | \$79,640  | Beth Israel Deaconess Med Ctr       | Preclinical Evaluation of Bacterially-Displayed Anti-HIV Antibodies to Prevent HIV Infection |
| 2007 | \$65,128  | UCLA Medical Center                 | Assessment of Drug-Resistance Mutation Fitness Costs Across HIV-1 Clades                     |
| 2007 | \$88,000  | Washington University               | HIV PI-Induced Insulin Resistance: Role of SOCS-1  |
| 2007 | \$59,246  | Tufts University School of Medicine | Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV+ Patients                  |
| 2007 | \$71,973  | Univ. of Massachusetts              | Molecular & Biologic Properties of Transmitted HIV-1 Variants in a Mother-Child Cohort       |

|      |           |   |   |
|------|-----------|---|---|
| 2006 | \$104,181 | Albany Medical College                        | Mechanisms of Naturally-Occurring HIV-1 Inhibitors  |
| 2006 | \$84,018  | Univ. of Colorado Health Sciences Center      | Alpha-1 Antitrypsin Inhibits HIV-1 (Extension funding)  |
| 2006 | \$97,196  | Cleveland Clinic                              | Analysis of Novel Mutagenic Compounds to Lead HIV to Error Catastrophe                                      |
| 2006 | \$88,000  | Univ. of Southern California                  | Design of Second Generation HIV-1 Integrase Inhibitors  |
| 2006 | \$90,273  | Univ. of California, Davis                    | Long-term Non-Progressor Resistance Factors   |
| 2006 | \$79,200  | Thomas Jefferson University                   | Role of Heterologous Hep C Virus RNA-Dependent RNA Polymerase in Human Cells...Enhancing RNAi Against HIV-1 |
| 2006 | \$85,800  | Medical College of Wisconsin                  | HIV Hiding in Mature Dendritic Cells Establish Viral Reservoirs   |
| 2005 | \$83,981  | Rush University Medical Center                | Evaluating the Role of Antigen-Specific Tcells in HIV Immunity  |
| 2005 | \$87,718  | George Washington University                  | Mechanisms of Atherogenic Effect of HIV-1 Infection   |
| 2005 | \$11,603  | Yale University School of Medicine            | CXCR4 Allosteric Agonists   |
| 2005 | \$82,098  | Wistar Institute                              | Mouse Model to Test Efficacy of HIV-1 Vaccines  |
| 2005 | \$110,000 | UMASS Medical School                          | Mechanism of HIV-1 Persistence in the Face of HAART   |
| 2005 | \$160,000 | CRI, New England                              | Randomized Controlled Trial of a Weekly Schedule of Five Days On / Two Days Off                             |
| 2004 | \$75,000  | University of Colorado Health Sciences Center | Alpha-1 Antitrypsin Inhibits HIV-1  |
| 2004 | \$60,000  | University of Pittsburgh                      | Evaluation of Novel Antiviral Targeting HIV-1 Vpr   |



|      |          |   |  |
|------|----------|---|--|
| 2004 | \$40,000 | Univ. of California, San Diego                  | Protecting Cells from HIV Infection & Destruction In Vivo  |
| 2004 | \$78,650 | Burnet Institute, Australia                     | Role of HIV Infection of Astrocytes in the Development of HIV-Ass'd Dementia                           |
| 2004 | \$65,100 | Johns Hopkins                                   | Targeting the HIV Macrophage Reservoir   |
| 2004 | \$75,000 | Aaron Diamond AIDS Research Ctr.                | Inhibition of Integrase-Mediated Viral Nuclear Transport   |
| 2004 | \$80,000 | Mount Sinai School of Medicine                  | Chemical Inhibitors for the HIV Tat/PCAF Complex   |
| 2003 | \$44,000 | Ohio State University                           | Impact of Anti-AIDS Drugs & Drug Resistance on HIV Evolution   |
| 2003 | \$79,200 | Mass. General Hospital                          | HIV-1/HCV Coinfection: Role of HCV-Specific Tcells in Complicating HIV-1 Infection & Therapy           |
| 2003 | \$71,500 | Mass. General Hospital                          | Comprehensive Assessment of HIV-1 Specific CTL Responses in Infected Chinese for Vaccine Design        |
| 2003 | \$75,000 | Global Alliance to Immunize Against AIDS (GAIA) | GAIA AIDS Vaccine Project/Bamako, Mali   |
| 2003 | \$60,000 | University of Southern California               | HIV Vaccine Development Utilizing a Goat Lentivirus  |
| 2003 | \$25,017 | The New York Blood Center                       | HIV-1 Entry Inhibitors Targeting Hydrophobic Cavity in gp120   |
| 2003 | \$88,062 | University of Miami                             | Longitudinal Assessment of Autologous Neutralizing Antibodies in Children Perinatally Infected w/HIV-1 |
| 2003 | \$38,500 | University of Southern California               | Epidemiology & Clinical Significance of PCP Colonization   |
| 2003 | \$75,000 | University of California, San Francisco         | Identification of the CD8+ Cell Anti-HIV Factor  |
| 2002 | \$55,000 | Univ. of Massachusetts                          | Determinants of Non-Progressive HIV-1 Infection in Women & Children                                    |

|      |           |   |  |
|------|-----------|---|--|
| 2002 | \$75,843  | Center for Blood Research                   | Subtype-Specific Regulation of HIV1 Gene Expression  |
| 2002 | \$65,000  | Rush-Presbyterian-St. Luke's Medical Center | Impact of IL-7 on HIV Infection of Naive Cells...Potential Role of IL-7 as an Immune Modulator   |
| 2002 | \$96,525  | CRI, New England                            | Maintenance HIV Suppression w/Cyclic Weekly HAART 5/2 Schedule   |
| 2002 | \$103,202 | Childrens Hospital Los Angeles              | Bone Size & Bone Mineral Density in HIV+ Children & Adolescents  |
| 2002 | \$83,113  | Washington University                       | Extension Grant from 2001 (see above)  |
| 2002 | \$32,141  | New Jersey Med. School                      | Prevalence of Anal HPV & Anal Dysplasia in HIV Seropositive Adolescent & Young Adult Males   |
| 2002 | \$79,200  | Dana-Farber Cancer Inst.                    | Viral Determinants & Mechanisms for HIV-1 Neurotropism & CNS Pathogenesis  |
| 2001 | \$72,050  | Cornell University                          | Role of CCR-5 in Interlukin-12 Production in HIV-1 Infection   |
| 2001 | \$79,200  | St. Luke's-Roosevelt Hospital Center        | Application of Molecular Techniques to the Study of HIV-Associated Lipodystrophy   |
| 2001 | \$58,267  | Georgetown University                       | Development of HHV-6 U94 As a Novel Anti-HIV Therapy   |
| 2001 | \$87,467  | Washington Univ. School of Medicine         | Rosiglitazone & Exercise Training: Effects on HIV+ People w/Insulin Resistance, Hypertriglyceridemia, & Adipose Tissue Maldistribution |
| 2001 | \$77,000  | Univ. of California, San Diego              | Lentiviral Vectors Interfering w/CD4 Downmodulation as an HIV Anti-viral Strategy  |
| 2001 | \$55,000  | Univ. of California, San Francisco          | Systemic Delivery of Tat and the Effects on HIV Replication and the Host   |
| 2001 | \$10,000  | Childrens Hope Foundation                   | Emergency Grant (9/11 Impact)  |

|      |           |                                    |   |
|------|-----------|------------------------------------|---|
| 2001 | \$50,000  | Aaron Diamond AIDS Research Center | Aggressive Antiviral Therapy During Acute HIV-1 Infection   |
| 2001 | \$50,072  | Schneider Childrens Hospital       | Siberian Ginseng: A Modulator of TH1-Like T-cell Cytokine mRNA & Cytokine Protein Expression in Pediatric HIV Infection |
| 2000 | \$25,000  | The Wistar Institute               | Extension Grant from 1998 (see above)   |
| 2000 | \$47,850  | University of Kentucky             | Analysis of Antiviral Efficacy of RRI   |
| 2000 | \$64,990  | UCLA School of Medicine            | Phase I Gene Therapy Study Using a Lentiviral Vector for Patients w/Multi-Drug Resistance to HIV                        |
| 2000 | \$91,707  | Washington University              | Characterizing Osteopenia in HIV+ People Treated w/ Protease Inhibitors   |
| 2000 | \$55,000  | Robert Wood Johnson Medical School | Extension Grant from 1999 (see above)   |
| 2000 | \$63,000  | UCLA School of Dentistry           | Role of Candida Species in Endodontic Infections in HIV+/AIDS Population & Its Effect on Endo. Treatment                |
| 2000 | \$26,675  | University Hospitals of Cleveland  | Pilot Trial to Evaluate Effect of Antioxidants in HIV+ Patients w/Lipodystrophy or Hyperlactatemia                      |
| 2000 | \$45,000  | State University of New York       | Generation of Anti-HIV Cytotoxic T-Lymphocytes Using Lentivirus Vectors   |
| 1999 | \$105,686 | University of Southern Cal.        | Extension Grant from 1998 (see above)   |
| 1999 | \$69,832  | The Rockefeller University         | Importance of Dendritic Cells in SIV delta nef Vaccines   |
| 1999 | \$53,381  | St. Louis University               | Enhancement of Anti-HIV Immunity by Sequential Immunization w/Heterologous Live Virus Vectors                           |
| 1999 | \$85,121  | Washington University              | Characterizing Diabetes & Lipid Disorders in HIV+ People Treated with Protease Inhibitors                               |

|      |           |  |  |
|------|-----------|--|--|
| 1999 | \$60,500  | Rush-Presbyterian-St. Luke's Med. Center | Mechanism(s) of Protection Against in utero HIV Transmission   |
| 1999 | \$50,000  | Robert Wood Johnson Medical School       | Development of a Tat-Antagonist Therapeutic for AIDS   |
| 1999 | \$74,970  | Mass. General Hospital                   | Artificial Thymus for HIV-Induced Immunodeficiency   |
| 1999 | \$30,000  | Tampa Bay Research Inst.                 | Extension Grant from 1998 (see above)  |
| 1999 | \$41,363  | City of Hope, CA                         | Extension Grant from 1997 (see above)  |
| 1999 | \$38,500  | Columbia University                      | Silencing Harmful Genes to Prevent Disease   |
| 1998 | \$65,093  | Oregon Health Sciences University        | Preclinical Evaluation of Anti-HIV Lipophilic Prodrugs   |
| 1998 | \$58,270  | Tampa Bay Research Institute             | Effects of Pinecone Extract (PC6) on the Progression of Murine AIDS  |
| 1998 | \$71,500  | Pediatric AIDS Foundation                | Pediatric CTL Responses and HIV Disease Progression  |
| 1998 | \$70,590  | Body Positive, Houston                   | Use of Anabolic Steroids, Optimum Nutrition, and Exercise Therapy for HIV+ Adult Male Patients                                   |
| 1998 | \$65,000  | CRIA, New York                           | Pilot Study of the Effect of Recombinant Human Growth Hormone (Serostim) in the Treatment of Truncal Obesity Associated with HIV |
| 1998 | \$75,000  | INSERM, France                           | Extension Grant from 1997 (see above)  |
| 1998 | \$100,000 | The Wistar Institute                     | Immune Function and Anti-HIV Resistance Following HAART  |
| 1998 | \$42,287  | University of Kentucky                   | Cloning of HIV-1 Genes in Tissue Culture for Drug Screening & Engineering of Therapeutic Antibodies Against HIV-1 Tat Protein    |
| 1998 | \$8,928   | University of Southern Cal.              | Extension Grant from 1997 (see above)  |

|      |           |  |   |
|------|-----------|--|---|
| 1998 | \$74,439  | UCLA School of Medicine                    | Factors Related to Appointment & Medication Non-Adherence in HIV+ Men and Women                                   |
| 1997 | \$40,645  | University of Kentucky                     | Effect of Folinic Acid on the Hematological Toxicity of Selected Medications Used in the Treatment of Chronic HIV |
| 1997 | \$78,969  | University of Miami                        | Evaluation of CD8 Immunologic Recovery After Subcutaneous IL2 Administration                                      |
| 1997 | \$45,000  | Community Research Initiative, New England | CD-4 Levels That Have Risen as a Result of Initiation of Protease Inhibitor Therapy                               |
| 1997 | \$50,500  | Community Research Initiative, Miami       | Joint Study with CRI New England  |
| 1997 | \$44,900  | Montrose Clinic, Houston                   | Clinical Director for HIV Research Staff Position   |
| 1997 | \$26,000  | AIDS Project of the Ozarks                 | Provide Clinical Trial Access to HIV+ Patients in SW Missouri   |
| 1997 | \$114,615 | University of Southern California          | Immune Responses to HIV in Humans Infected with a Novel Virus   |
| 1997 | \$39,772  | City of Hope, CA                           | Anti-HIV Activity in Herbs: A Molecular Characterization  |
| 1997 | \$75,000  | INSERM, France                             | Study of Non-Progressor HIV Patients  |
| 1996 | \$8,560   | Mercy Hospital, Miami                      | Clinical Trial of Cats Claw in Asymptomatic HIV+ Subjects   |
| 1996 | \$27,500  | Oregon Health Sciences University          | Extension of 1995 Grant (see above)   |
| 1996 | \$24,000  | University of Miami                        | Efficacy of Pentoxifylline in the Treatment of Pruritic Papular Eruption of HIV+ Patients                         |
| 1995 | \$30,000  | University of Miami                        | Treatment of Scabies with Ivermectin  |
| 1995 | \$29,759  | Oregon Health Sciences University          | Combined Modality Approaches to Treat Retroviral Disease  |
| 1995 | \$15,510  | Mercy Hospital, Miami                      | Clinical Trial of Thalidomide in the Treatment of HIV-Associated KS   |

